ALZAMEND NEURO, INC. Shareholders' Equity
ALZAMEND NEURO, INC. (ALZN) had Shareholders' Equity of $5.80 million as of 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-09-10
- 2026-07-31: Stockholders' Equity Attributable to Parent $5.80M.
- 2026-04-30: Stockholders' Equity Attributable to Parent $733.21K.
- 2026-01-31: Stockholders' Equity Attributable to Parent $2.20M; Stockholders' Equity Attributable to Parent as first filed $2.18M.
- 2025-10-31: Stockholders' Equity Attributable to Parent $4.37M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-07-31 | $5.80M 10-Q · filed 2026-09-10 | |
| 2026-04-30 | $733.21K 10-Q · filed 2026-09-10 | |
| 2026-01-31 | $2.20M 10-K · filed 2026-07-22 | $2.18M 10-Q · filed 2026-03-11 |
| 2025-10-31 | $4.37M 10-Q · filed 2026-03-11 | |
| 2025-07-31 | $5.34M 10-Q · filed 2026-09-10 | |
| 2025-04-30 | $3.97M 10-Q · filed 2026-09-10 | |
| 2025-01-31 | $3.45M 10-Q · filed 2026-03-11 | |
| 2024-10-31 | $3.75M 10-Q · filed 2026-03-11 | |
| 2024-07-31 | -$1.21M 10-Q · filed 2025-12-09 | |
| 2024-04-30 | -$2.59M 10-Q · filed 2026-03-11 | |
| 2024-01-31 | -$4.26M 10-Q · filed 2024-03-25 | |
| 2023-10-31 | -$2.68M 10-Q · filed 2023-12-15 | |
| 2023-07-31 | -$112.88K 10-Q · filed 2023-12-15 | |
| 2023-04-30 | $3.05M 10-K · filed 2024-07-30 | |
| 2023-01-31 | $5.86M 10-Q · filed 2023-03-15 | |
| 2022-10-31 | $8.79M 10-Q · filed 2023-12-15 | |
| 2022-07-31 | $11.18M 10-Q · filed 2023-12-15 | |
| 2022-04-30 | $13.35M 10-Q · filed 2023-12-15 | |
| 2022-01-31 | $11.96M 10-Q · filed 2023-03-15 | |
| 2021-10-31 | $13.03M 10-Q · filed 2023-03-15 | |
| 2021-07-31 | $15.34M 10-Q · filed 2022-12-12 | |
| 2021-04-30 | $2.01M 10-K · filed 2023-07-27 | |
| 2021-01-31 | -$1.30M 10-Q · filed 2022-03-15 | |
| 2020-10-31 | -$666.77K 10-Q · filed 2022-03-15 | -$666.77K 10-Q · filed 2021-12-13 |
| 2020-07-31 | $25.87K 10-Q · filed 2021-12-13 | |
| 2020-04-30 | $821.71K 10-K · filed 2022-07-19 | |
| 2019-04-30 | $316.92K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |